# GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study

> **NCT03751761** · PHASE1,PHASE2 · COMPLETED · sponsor: **Asan Medical Center** · enrollment: 58 (actual)

## Conditions studied

- Metastatic Gastric Cancer

## Interventions

- **DRUG:** durvalumab, tremelimumab, paclitaxel

## Key facts

- **NCT ID:** NCT03751761
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-11
- **Primary completion:** 2023-08-30
- **Final completion:** 2023-08-30
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2024-02-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03751761

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03751761, "GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03751761. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*